α-Tocotrienol and Redox-Silent Analogs of Vitamin E Enhances Bortezomib Sensitivity in Solid Cancer Cells through Modulation of NFE2L1
Open Access
- 27 May 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (11) , 9382
Abstract
Proteasome inhibitors (PIs) have emerged as an attractive novel cancer therapy. However, most solid cancers are seemingly resistant to PIs. The activation of transcription factor Nuclear factor erythroid 2 related factor-1 (NFE2L1) has been characterized as a potential resistance response to protect and restore proteasome activity in cancer cells. In this study, we demonstrated that α-Tocotrienol (T3) and redox-silent analogs of vitamin E (TOS, T3E) enhanced the sensitivity of bortezomib (BTZ), a proteasome inhibitor, in solid cancers through modulation of NFE2L1. In BTZ treatment, all of T3, TOS, and T3E inhibited an increase in the protein levels of NFE2L1, the expression levels of proteasome-related proteins, as well as the recovery of proteasome activity. Moreover, the combination of one of T3, TOS, or T3E and BTZ induced a significant decrease in cell viability in solid cancer cell lines. These findings suggested that the inactivation of NFE2L1 by T3, TOS, and T3E is essential to potentiate the cytotoxic effect of the proteasome inhibitor, BTZ, in solid cancers.Keywords
Funding Information
- Inoue Enryou Memorial Foundation of Toyo University
This publication has 39 references indexed in Scilit:
- Targeting the ubiquitin–proteasome system for cancer therapyExpert Opinion on Therapeutic Targets, 2013
- γ‐Tocotrienol is a novel inhibitor of constitutive and inducible STAT3 signalling pathway in human hepatocellular carcinoma: potential role as an antiproliferative, pro‐apoptotic and chemosensitizing agentBritish Journal of Pharmacology, 2010
- Transcription Factor Nrf1 Mediates the Proteasome Recovery Pathway after Proteasome Inhibition in Mammalian CellsMolecular Cell, 2010
- Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2)Oncogene, 2009
- A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cellsLife Sciences, 2009
- Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Increased Proteasome Activity, Ubiquitin-Conjugating Enzymes, and eEF1A Translation Factor Detected in Breast Cancer TissueCancer Research, 2005
- Induction of cytotoxicity in human lung adenocarcinoma cells by 6‐O‐carboxypropyl‐α‐tocotrienol, a redox‐silent derivative of α‐tocotrienolInternational Journal of Cancer, 2005
- High plasma proteasome levels are detected in patients with metastatic malignant melanomaBritish Journal of Dermatology, 2005
- Characterization of Cellular Uptake and Distribution of Vitamin EAnnals of the New York Academy of Sciences, 2004